CDMO Service

cGMP Peptide Synthesis

Pharmaceutical-grade peptide manufacturing in fully validated cGMP facilities for IND, clinical, and commercial supply.

Service Overview

SynthAxis operates purpose-built cGMP peptide synthesis suites compliant with ICH Q7 guidelines. Our platform supports therapeutic peptide APIs from early-stage IND enabling batches through Phase I–III clinical supply and commercial manufacturing.

We employ automated SPPS platforms with advanced orthogonal protection strategies, high-resolution reversed-phase HPLC purification, and comprehensive analytical packages including identity confirmation, purity determination, residual solvent testing, and microbiological analysis.

Every cGMP batch is supported by a complete batch manufacturing record (BMR), certificate of analysis (COA), and full regulatory documentation package to support your submission requirements.

Key Capabilities

ICH Q7-compliant manufacturing facilities
Automated Fmoc SPPS at multi-gram to kilogram scale
Advanced orthogonal protection group strategies
High-resolution preparative HPLC purification
Full residual solvent testing (ICH Q3C)
Peptide content and counterion determination
Microbial limits and endotoxin testing
Batch manufacturing records and COA for every lot
Method development and validation support
Stability study design and execution
IND/NDA regulatory filing support
Tech transfer and commercial scale-up services